The recently developed Open Targets platform consolidates a wide range of comprehensive evidence associating known and potential drug targets with human diseases. We have harnessed the integrated data from this platform for novel drug repositioning opportunities. Our computational workflow systematically mines data from various evidence categories and presents potential repositioning opportunities for drugs that are marketed or being investigated in ongoing human clinical trials, based on evidence strength on target–disease pairing. We classified these novel target–disease opportunities in several ways: (i) number of independent counts of evidence; (ii) broad therapy area of origin; and (iii) repositioning within or across therapy areas. Finally, we elaborate on one example that was identified by this approach.

最近开发的开放目标平台整合了广泛的综合证据，将已知和潜在的药物目标与人类疾病相关联。我们利用了来自该平台的集成数据来寻找新的药物重新定位机会。我们的计算工作流程会根据目标疾病配对的证据强度，系统地挖掘各种证据类别的数据，并为正在进行的人类临床试验中正在销售或正在研究的药物提供潜在的重新定位机会。我们通过以下几种方式对这些新颖的目标疾病机会进行了分类：（i）独立证据的数量；（ii）广泛的治疗起源地区；（iii）在治疗区域之内或之间重新定位。最后，我们详细说明一种通过这种方法确定的示例。